Coeptis announces $1.7 million from new AI marketing deals

WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), a biopharmaceutical company with a market capitalization of $14.41 million, has reported securing five new clients for its NexGenAI Affiliates Network platform, with managed services agreements valued at $1.25 million and an expected $450,000 in recurring monthly revenue. The stock has shown strong momentum, gaining over 27% in the past week. This development marks the initial success of the company's AI-driven marketing solutions in the biopharma industry.

President and CEO Dave Mehalick expressed optimism about the early adoption of the NexGenAI platform, emphasizing its role in enhancing customer engagement and marketing strategies. Coeptis anticipates a rapid expansion of the platform throughout 2025, aiming to solidify its market position and contribute to revenue growth. According to InvestingPro analysis, the company currently maintains a FAIR financial health score of 2.19, though it faces challenges with short-term liquidity as indicated by a current ratio of 0.4.

Artificial Intelligence is increasingly influential in marketing, offering businesses the ability to personalize campaigns and analyze consumer behavior more effectively. Coeptis' platform is part of this technological evolution, aiming to improve operational efficiencies and foster innovative consumer engagement strategies.

Mehalick highlighted the company's intention to continue pursuing contracts with potential clients, indicating a strategic focus on growth and market expansion. The current success is seen as a stepping stone to further achievements in the sector.

Coeptis Therapeutics Holdings, Inc., along with its subsidiaries, is involved in developing cell therapy platforms for various diseases and has licensed several promising technologies. The NexGenAI Affiliates Network platform represents their venture into leveraging AI for marketing and operational advancements.

This announcement is based on a press release statement and contains forward-looking projections that involve risks and uncertainties. The actual results may differ from these expectations due to numerous factors, including market conditions and regulatory challenges. InvestingPro subscribers have access to 11 additional key insights about COEP, including detailed analysis of its market performance and financial health metrics.

In other recent news, Coeptis Therapeutics has announced a series of strategic developments. The biopharmaceutical company has initiated a 1-for-20 reverse stock split, aiming to meet the Nasdaq Capital Market's minimum bid price requirement. Coeptis has also approved the acquisition of the NexGenAI Affiliates Network platform, which is expected to offer AI-powered marketing software and robotic process automation capabilities.

Additionally, the company has launched a new division, Coeptis Technologies, targeting the data security sector. Coeptis has also expanded its license agreement with Deverra Therapeutics for the use of unmodified natural killer cells for pandemic preparedness and emergency use.

Shareholders have approved key proposals including the election of seven director nominees, the appointment of Astra Audit & Advisory, LLC as the independent registered public accounting firm, and an amendment authorizing a reverse stock split.

Despite facing financial challenges and retracting its financial statements for several periods in 2023 and 2024 due to accounting errors, Coeptis has appointed Astra Audit & Advisory, LLC as its new independent registered public accounting firm. The company has also secured an extension to remain listed on the Nasdaq until January 15, 2025, contingent on compliance with the minimum bid price requirement. These are the recent developments at Coeptis Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.